- Open Access
Evaluation of several adjuvants in avian influenza vaccine to chickens and ducks
© Liu et al; licensee BioMed Central Ltd. 2011
- Received: 7 April 2011
- Accepted: 26 June 2011
- Published: 26 June 2011
The effects of three different adjuvants, mineral oil, Montanide™ ISA 70M VG, and Montanide™ ISA 206 VG, were evaluated on reverse genetics H5N3 avian influenza virus cell cultured vaccine. The immune results of SPF chickens after challenging with highly pathogenic avian influenza (HPAI) virus demonstrated that mineral oil adjuvant group and 70M adjuvant group provided 100% protection efficiency, but 206 adjuvant group provided only 40%. Statistical analysis indicated that the protection effects of mineral oil adjuvant group and the 70M adjuvant showed no significant difference to each other, but with significant difference to 206 adjuvant group. All three groups could induce high titres of antibody after immunizing SPF ducks, but there was no significant difference among them. The immunization effect of 70M adjuvant group on SPF chickens were the best and showed significant difference compared with optimized 70Mi Montanide™ eight series adjuvants groups. These results suggest that 70M adjuvant could be a novel adjuvant for preparing avian influenza vaccine.
- Avian Influenza
- Avian Influenza Virus
- Highly Pathogenic Avian Influenza
- Specific Pathogen Free
- Primary Immunization
H5 subtype highly pathogenic avian influenza (HPAI) viruses could cause severe disease and enormous economical loss to poultry farms. They could also cross the species barrier to infect mammals. In particular, the direct transmission of avian influenza viruses to humans without the pigs as "vessel" might be seriously endangered the poultry industry and human health [1–3]. It is very important to strengthen bird influenza surveillance, prevention and control work. The main control strategies for H5N1 subtype HPAI involve increased bio-security, surveillance, and vaccination, however, the vaccination is an effective and economic strategy in controlling the prevalence of this disastrous disease. At present, the widely used conventional inactivated H5 subtype bird influenza virus is from allantoic fluids of embryonated chicken eggs. It is necessary to solve many problems in vaccine development, including the difficulty in vaccine strains construction by conventional method , the serious byproducts pollution from embryonated chicken eggs in vaccines production progress, and the difficulty to differentiate nature infected and routine immunized birds. A new type of vaccine production system which could replace embryonated chicken eggs and differentiate between the infected and the immunized birds is urgent need.
The modern molecular biological techniques provide a new approach for new type of influenza vaccine design . Compare to traditional vaccine development, the new influenza vaccine development trend should have the same or no less protective effects, saving times in the vaccine production process, alleviating environmental pollution, providing a higher levels of bio-security.
The reverse genetics H5N3 (rH5N3) avian influenza vaccine strain was successfully constructed by the reverse genetics technique . The prepared rH5N3 vaccine strain, which could discriminate the infected birds from the immunized birds by N3 marker [7, 8], can replicate effectively in MDCK cell lines . To further promote vaccine effects and scan the optimal adjuvant, the rH5N3 virus was used in this study to evaluate different adjuvants.
The rH5N3 avian influenza vaccine strain was previously constructed by reverse genetics . Briefly, the six internal genes came from high-yield influenza virus A/Goose/Dalian/3/2001 (H9N2), hemagglutinin (HA) gene from A/Goose/HLJ/QFY/2004(H5N1), and neuraminidase (NA) gene from A/Duck/Germany/1215/73(H2N3) reference strain. The HA gene was modified by the deletion of four basic amino acids of the connecting peptide between HA1 and HA2. The rH5N3 was generated by co-transfection to mixed Madin-Darby canine kidney (MDCK) cell lines and Human embryonic kidney (HEK) 293T cell lines. Stock virus was made with MDCK cells. All experiments with H5N1 subtype influenza virus were performed in Bio-Safety Levels 3+ containment laboratory.
The three-week-old specific pathogen free (SPF) White Leghorn chickens and SPF ducks were used in this experiment offered by Experimental Animal Center of the Harbin Veterinary Research Institute. All animals were housed in the stainless steel isolation cabinets that were ventilated under negative pressure with HEPA-filtered air.
HI antigen and adjuvants
The H5 subtype avian influenza HI antigen and domestic mineral oil adjuvant provided by Harbin Wei Ke Biotechnology Development Company of the HVRI. Montanide™ ISA 206 VG adjuvant, Montanide™ ISA 70M VG adjuvant and Montanide™ ISA 70 essai Mi (i = 1-8) adjuvant provided by France Seppic Shanghai Branch .
Preparation of vaccine
The cell-cultured rH5N3 avian influenza virus was inactivated by 1‰ formalin. The inactivated virus mixed with mineral oil adjuvant at 1:2 (Vol/Vol) and then emulsified as conventional methods. 70M, 70Mi, and 206 adjuvant vaccine prepared as described by Seppic protocols, respectively. Briefly, inactivated virus mixed with 70M and 70Mi adjuvant at a ratio of 2.6:7.4 (v/v), with 206 adjuvant at a ratio of 4.6:5.4 (v/v), respectively, and then emulsified as described by Seppic protocols.
Immunization of animals
Boosting date a
Challenging date b
Collection of swab c
2, 3, 4, 6, 8, and 13 w after primary immunization
13 w after primary immunization
3 w p.v. d
0 day before initial immunization, 2, 6, and 9 w after primary immunization
70 Mi(i = 1-8)
3 w p.v.
2, 3, 4, 6, 8, and 13 w after primary immunization
13 w after primary immunization
3, 7, and 10 days p.c. e
In part II experiments, thirty two three-week-old SPF ducks were randomly divided into four groups of eight birds each. Three groups were immunized with mineral oil adjuvant vaccine, 70M adjuvant vaccine, and 206 adjuvant vaccine with 0.25 ml antigen per duck in the neck, respectively. Group four as control injected with 0.5 ml PBS per duck. The boosting immunization was conducted three weeks after primary immunization with the same dose (Table 1).
In part III experiments, one hundred three-week-old SPF chickens were randomly divided into ten groups of ten birds. The first group was immunized with 70M adjuvant vaccine. The groups 2-9 inoculated with 70Mi (i = 1-8) adjuvant vaccine, respectively. SPF chickens from groups 2-9 vaccinated same as to the first group. Group 10 as control injected with 0.3 ml PBS each chicken. The boosting immunization was performed three weeks followed primary immunization with the same dose (Table 1).
Monitoring of antibody titres
2, 3, 4, 6, 8, and 13 weeks after primary immunization, all birds were bled for sera collecting. 0 day before initial immunization, 2 weeks after primary immunization, 3 and 6 weeks after boosting immunization, all ducks were bled for sera collecting. The dynamic changes of antibody titres were detected by HI test.
Each chicken from five groups of part I and ten groups of part III were challenged with H5N1 HPAI virus A/Gs/HLJ/QFY/04(H5N1) 106 EID50 through intranasal and eye drop administration. Adjuvant effects for rH5N3 vaccines were evaluated after 13 weeks post-vaccination. Morbidity and mortality was observed daily for 10 days. Cloaca and throat swabs of birds of part III were collected at 3, 7, and 10 days post-challenge for virus detection.
A Student t-test was used to analyze the results of the HI assay for the levels of antibodies.
Dynamic changes of antibody titres
0 day before initial immunization, 3 weeks after primary immunization, 3 and 6 weeks post boosting immunization, the ducks antibody titres of four groups in part II were detected by HI test (Figure 2). The results indicated that all three groups can induce good immune response and produce similar level of HI antibody. There were no statistically significant differences (P > 0.05) among mineral oil adjuvant group, 70M adjuvant group, and 206 adjuvant group. The ducks of control groups did not elicit HI antibody.
Birds had inflammation at injection site in mineral oil adjuvant group, but other groups did not show any clinical and pathological signs.
Study of challenge and protection
The HI antibody titres of chickens of Part I post-vaccination and protection efficiency post-challenge
The HI antibody titre(log2) p.v. a
The HI antibody titre(log2) p.c. b
The HI antibody titre of chickens in Part III post-vaccination and protection efficiency post-challenge
The antibody HI titre (log2) p.v. a
The HI antibody titre(log2) p.c. b
An effective vaccine needs not only good antigens but also preferable adjuvant to enhance the immunogenicity of antigen. The adjuvant was used to enhance humoral and cellular immune responses, but adjuvant would also lead to side-effect to bodies, such as inflammation, tissue damage and pain . Oil emulsion vaccine could promote antibody titre and extend immunity period. However, mineral oil long term stand at the injection site, and caused inflammation and local tissue necrosis, lead commercial value of the birds lower.
In present experiment, mineral oil, 70M, and 206 adjuvant were used to evaluate adjuvant effects. 70M adjuvant and 206 adjuvant were oil in water (W/O) and water in oil (W/O/W) adjuvant based on purified mineral, respectively. The previous studies showed that the vaccine combined 70M adjuvant, Freund's complete adjuvant, or incomplete Freund's adjuvant were able to induce similar antibody responses, but 70M adjuvant vaccine caused obviously much less inflammatory response after inoculation [11–14]. The avian influenza vaccine emulsified with 70M adjuvant prepared provided a good protection to immunized chicken [15–17]. Vaccine conjugated 70M adjuvant induced not only humoral immune responses, but also strong cellular immune responses after immunizing mice . 70M and 206 adjuvant could provide the immune enhancing effects on Eimeria acervulina vaccine .
In this experiment, the antibodies of SPF chicken induced by 70M adjuvant vaccine or mineral oil adjuvant vaccine were higher than that of protective threshold two weeks post-inoculation, but 206 adjuvant vaccine and antigen without adjuvant did not. The antibody levels elicited by 206 adjuvant group achieved protective threshold three weeks later and reached the highest level after four weeks then began to decline, but it was no longer able to provide theoretical protection 13 weeks after immunization, which is consist with porcine circle virus disease inactive vaccine . In part I and II experiments, the antibody titres of 70M adjuvant group were higher than that of the mineral oil adjuvant group, but the differences between two groups were not significant (P > 0.05) statistically, while the two groups showed significant differences (P < 0.01) compared to 206 adjuvant group in part I but not in part II experiments. In part II, 206 adjuvant group induced the similar immune responses to 70M adjuvant group and mineral oil adjuvant group of ducks.
We speculated that 206 adjuvant was a kind O/W type adjuvant, it released into the lymphoid tissue rapidly after immunization and leaded to inefficiency to chickens, while 70M adjuvant and mineral oil adjuvant were a type of W/O adjuvant and could be stored at the injection site and release slowly. Another reason maybe due to the chickens, ducks and pigs are different species, their immune systems possessed differences leading to the distinguishing immune responses elicited by 206 adjuvant vaccines. However, the real reason was unknown and to be further studied.
Since 70 M adjuvant induced better immune effects to the chickens and ducks, the French Seppic company optimized 70M adjuvant and prepared eight 70M Series of adjuvant, Montanide™ ISA 70 essai Mi (i = 1-8) adjuvants. Immunity and challenge experiments to SPF chickens showed that the antibody induced by 70M adjuvant group surpassed protective threshold two weeks after immunization, while the other groups were lower than that. Three weeks later, only 70M6 adjuvant group achieved that level. All the other vaccine groups (70 M1, 70M3-5, 70M7, and 70M8), the titres of antibody stay low from two weeks to thirteen weeks post-vaccination, and to 13 weeks each groups antibody titre was lower than the threshold while 70M2 and 70M6 adjuvant groups antibody levels remained at 7log2 above, 70M adjuvant group reached to 9log2 above. 70M2 and 70M6 adjuvant groups achieved to the highest levels of antibody at six weeks post-immunization, and the other groups were at eight weeks post-immunization. Challenge experiment results showed that 70M, 70M2, and 70M6 adjuvant groups could provide 100% protection. The results suggested that 70M adjuvant and 70M6 adjuvant groups had good effects in all groups, and 70M adjuvant group was the best one with statistically significant differences (P < 0.01) to all other groups.
There were no visible clinical and pathological signs at birds inoculation sites two weeks after immunization of the 70M adjuvant vaccine, 70Mi Series adjuvant vaccines, and 206 adjuvant vaccines, suggesting that all these Seppic adjuvant had smaller side reactions. 70M adjuvant could be best as a new type of adjuvant applied in the production of avian influenza vaccines.
This work was supported by Modern Agro-industry Technology Research System (CARS-43-10) and Scientific and Technological Support Scheme (grant 2006 BAD06A05).
- Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y: Evolution and ecology of influenza A virus. Microbiol Rev 1992, 56: 152-79.PubMed CentralPubMedGoogle Scholar
- Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, et al.: Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004, 430: 209-13. 10.1038/nature02746View ArticlePubMedGoogle Scholar
- Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al.: Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005, 352: 333-40. 10.1056/NEJMoa044021View ArticlePubMedGoogle Scholar
- Kilbourne D: Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ 1969, 41: 643-5.PubMed CentralPubMedGoogle Scholar
- Subbarao K, Katz JM: Influenza vaccines generated by reverse genetics. Curr Top Microbiol Immunol 2004, 283: 313-42.PubMedGoogle Scholar
- Liu M, Zhang Y, Liu CG, Pan WQ, Liu CN, Yang T: Generation High Yield Vaccine Strain Wholly Derived from Avian Influenza Viruses by Reverse Genetics. Chinese Journal of Biotechnology 2006, 22: 720-6. 10.1016/S1872-2075(06)60053-8View ArticlePubMedGoogle Scholar
- Liu M, He S, Walker D, Zhou N, Perez DR, Mo B, et al.: The influenza virus gene pool in a poultry market in South central China. Virology 2003, 305: 267-75. 10.1006/viro.2002.1762View ArticlePubMedGoogle Scholar
- Liu M, Liu CG, Zhang Y, Yang T: The NA Gene of N3 Avian influenza virus Expressed in Insect Cells. Progress in Veterinary Medicine 2005, 26: 50-4.Google Scholar
- Veterinary vaccine adjuvants[http://www.seppic.com/animal-health/vaccine-adjuvant-@/993/view-1111-category.html]
- Harold F, Stills J: Adjuvants and Antibody Production: Dispelling the Myths Associated with Freund's Complete and Other Adjuvants. ILAR Journal 2005, 46: 280-93.View ArticleGoogle Scholar
- Johnston BA, Eisen H, Fry D: An evaluation of several adjuvant emulsion regimens for the production of polyclonal antisera in rabbits. Lab Anim Sci 1991, 41: 15-21.PubMedGoogle Scholar
- Leenaars PP, Hendriksen CF, Angulo AF, Koedam MA, Claassen E: Evaluation of several adjuvants as alternatives to the use of Freund's adjuvant in rabbits. Vet Immunol Immunopath 1994, 40: 225-241. 10.1016/0165-2427(94)90022-1View ArticleGoogle Scholar
- Leenaars PP, Hendriksen CF, Koedam MA, Claassen I, Claassen E: Comparison of adjuvants for immune potentiating properties and side effects in mice. Vet Immunol Immunopath 1995, 48: 123-38. 10.1016/0165-2427(94)05413-MView ArticleGoogle Scholar
- Leenaars PP, Koedam MA, Wester PW, Baumans V, Claassen E, Hendriksen CF: Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice. Lab Anim 1998, 32: 387-406. 10.1258/002367798780599884View ArticlePubMedGoogle Scholar
- Choi JG, Lee YJ, Kim YJ, Lee EK, Jeong OM, Sung HW, et al.: An inactivated vaccine to control the current H9N2 low pathogenic avian influenza in Korea. J Vet Sci 2008, 9: 67-74. 10.4142/jvs.2008.9.1.67PubMed CentralView ArticlePubMedGoogle Scholar
- James CM, Foong YY, Mansfield JP, Fenwick SG, Ellis TM: Use of tetanus toxoid as a differentiating infected from vaccinated animals (DIVA) strategy for sero-surveillance of avian influenza virus vaccination in poultry. Vaccine 2007, 25: 5892-901. 10.1016/j.vaccine.2007.05.023View ArticlePubMedGoogle Scholar
- James CM, Foong YY, Mansfield JP, Vind AR, Fenwick SG, Ellis TM: Evaluation of a positive marker of avian influenza vaccination in ducks for use in H5N1 surveillance. Vaccine 2008, 26: 5345-51. 10.1016/j.vaccine.2008.08.008View ArticlePubMedGoogle Scholar
- Deville S, Pooter AD, Lainé-Prade V, Cote M, Ascarateil S, Aucouturier J, et al.: Influence of adjuvant formulation on induced host protection in a mouse vaccination model against Trichinella spiralis. In XIth International Conference on Trichinellosis, California: Manchester Conference Center University of San Diego San Diego Edited by: Douglas F. 2004, 48.Google Scholar
- Jang SI, Lillehoj HS, Lee SH, Lee KW, Park MS, Bauchan GR, et al.: Immunoenhancing effects of Montanide ISA oil-based adjuvants on recombinant coccidia antigen vaccination against Eimeria acervulina infection. Vet Parasitol 2010, 172: 221-8. 10.1016/j.vetpar.2010.04.042View ArticlePubMedGoogle Scholar
- Liu CM, Wei YW, Zhang CF, Zhang ZX, Yuang J: Comparison of adjuvant for porcine circovirus type 2 inactivated vaccines. Chinese Journal of Preventive Veterinary Medicine 2007, 29: 690-3.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.